

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(10) International Publication Number

WO 2014/107281 A1

(43) International Publication Date  
10 July 2014 (10.07.2014)

(51) International Patent Classification:  
*A61F 13/00* (2006.01)      *A61M 27/00* (2006.01)  
*A61M 1/00* (2006.01)      *A61F 13/02* (2006.01)

(21) International Application Number:  
PCT/US2013/074763

(22) International Filing Date:  
12 December 2013 (12.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/748,711      3 January 2013 (03.01.2013)      US

(71) Applicant: KCI LICENSING, INC. [US/US]; Legal Department - Intellectual Property, P.O. Box 659508, San Antonio, TX 78265-9508 (US).

(72) Inventors: ROBINSON, Timothy, Mark; 27 Wellington Terrace, Basingstoke, Hampshire RG23 8HH (GB). LOCKE, Christopher, Brian; 6 Bosworth Mews, Bournemouth, Dorset BH9 3SD (GB).

(74) Agents: WELCH, Gerald, T. et al.; SNR Denton US LLP, P.O. Box 061080, Wacker Drive Station, Willis Tower, Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MOISTURE ABSORBING SEAL




FIG. 1

(57) Abstract: A sealing drape may be suitable for use with a reduced-pressure treatment system for treating a tissue site. The sealing drape may have an interior surface adapted for positioning adjacent to a peripheral surface of the tissue site. The sealing drape may include a sealing material and an absorbent material. The sealing material may be hydrophobic and substantially free of hydrophilic components. Further, the sealing material may be positioned between the interior surface of the sealing drape and the absorbent material. The sealing drape may be used with a manifold for positioning at the tissue site, a reduced-pressure interface, and a reduced-pressure source. Methods of manufacture are also disclosed.

WO 2014/107281 A1

## MOISTURE ABSORBING SEAL

### RELATED APPLICATION

**[0001]** This application claims the benefit, under 35 USC § 119(e), of the filing of U.S. Provisional Patent Application Serial Number 61/748,711, entitled “Moisture Absorbing Seal,” filed January 3, 2013, which is incorporated herein by reference for all purposes.

### TECHNICAL FIELD

**[0002]** The following subject matter relates generally to tissue treatment systems and, more particularly, but not by way of limitation, to medical sealing drapes and systems including medical sealing drapes.

### BACKGROUND

**[0003]** Known tissue treatment systems may use a sealing drape to provide a fluid seal about a tissue site requiring treatment. Sealing around particular anatomical areas of the tissue site can be complicated and a leak-free seal is often difficult to achieve and maintain. Typical sealing drape materials may lack a sufficiently conformable adhesive capable of flowing into creases and cracks around the tissue site to achieve a good seal. Current materials may also suffer from being unable to transfer moisture away from the tissue site. Thus, if the sealing drape remains in place for an extended period of time, moisture present near the tissue site can cause maceration of the tissue and the formation of leaks between the tissue site and the sealing drape. Accordingly, improvements to sealing and moisture transfer capabilities for sealing drapes are desirable.

## SUMMARY

**[0004]** Shortcomings with certain aspects of known tissue treatment systems and methods utilizing sealing drapes are addressed as shown and described in a variety of illustrative, non-limiting embodiments herein. Other features and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.

**[0005]** In some embodiments, a reduced-pressure system for treating a tissue site may include a manifold, a sealing drape, and a reduced-pressure interface. The manifold may be adapted to be positioned adjacent the tissue site and to distribute reduced pressure to the tissue site. The sealing drape may have an interior surface and an external surface. The interior surface of the sealing drape may be adapted to cover the manifold and the tissue site to provide a sealed space between the interior surface of the sealing drape and the tissue site. Additionally, the sealing drape may include a sealing material and an absorbent material. The sealing material may be hydrophobic and substantially free of hydrophilic components. The absorbent material may be associated with the sealing material such that the sealing material may be positioned between the interior surface of the sealing drape and the absorbent material. The reduced-pressure interface may be adapted to deliver reduced-pressure. The reduced-pressure interface may be in fluid communication with the sealed space and the manifold.

**[0006]** In some embodiments, a sealing drape for treating a tissue site may include an interior surface, an external surface, a sealing material, and an absorbent material. The interior surface may be adapted to be positioned adjacent a peripheral surface surrounding the tissue site and to overlap the peripheral surface to provide a sealed space between the sealing drape and the tissue site. The sealing material may include a fluid permeable, hydrophobic material substantially free of hydrophilic components. The absorbent material may be disposed in the sealing material such that the sealing material may be positioned between the interior surface of the sealing drape and the absorbent material. The absorbent material may be adapted to absorb fluid communicated through the sealing material.

**[0007]** In some embodiments, a method of manufacturing a sealing drape for treating a tissue site may include the steps of: providing a sealing material; providing an absorbent material; and disposing the absorbent material in the sealing material. The sealing material may be hydrophobic and substantially free of hydrophilic components.

**[0008]** In some embodiments, a reduced-pressure system for treating a tissue site may include a manifold, a sealing drape, and a reduced-pressure interface. The manifold may be adapted to be positioned adjacent the tissue site and to distribute reduced pressure to the tissue site. The sealing drape may have an interior surface and an external surface. The interior surface of the sealing drape may be adapted to be positioned adjacent a peripheral surface surrounding the tissue site and to cover the manifold and the tissue site to provide a sealed space between the interior surface and the tissue site. Further, the sealing drape may be adapted to extend beyond the tissue site and to overlap the peripheral surface. Additionally, the sealing drape may include a sealing material and an absorbent material. The sealing material may be hydrophobic and substantially free of hydrophilic components. The absorbent material may be associated with the sealing material such that the sealing material may be positioned between the interior surface of the sealing drape and the absorbent material. The reduced-pressure interface may be adapted to deliver reduced-pressure. The reduced-pressure interface may be in fluid communication with the sealed space and the manifold.

**[0009]** In some embodiments, a method for treating a tissue site may include the steps of positioning a sealing drape adjacent a peripheral surface surrounding the tissue site, the sealing drape extending beyond the tissue site and overlapping the peripheral surface; and transferring moisture away from the peripheral surface through the sealing drape.

## BRIEF DESCRIPTION OF THE DRAWINGS

**[0010]** A more complete understanding of this specification may be obtained by reference to the following detailed description when taken in conjunction with the accompanying drawings wherein:

**[0011]** FIGURE 1 is a side view, with a portion shown in cross section, of an illustrative embodiment of a reduced-pressure treatment system depicting an illustrative embodiment of a sealing drape;

**[0012]** FIGURE 2 is a perspective view of another illustrative embodiment of a sealing drape suitable for use with the reduced-pressure treatment system of FIGURE 1;

**[0013]** FIGURE 3 is a perspective view of another illustrative embodiment of a sealing drape suitable for use with the reduced-pressure treatment system of FIGURE 1;

**[0014]** FIGURE 4 is a perspective, exploded view of another illustrative embodiment of a sealing drape suitable for use with the reduced-pressure treatment system of FIGURE 1;

**[0015]** FIGURE 5 is a perspective, exploded view of another illustrative embodiment of a sealing drape suitable for use with the reduced-pressure treatment system of FIGURE 1; and

**[0016]** FIGURE 6 is a perspective, exploded view of another illustrative embodiment of a sealing drape suitable for use with the reduced-pressure treatment system of FIGURE 1.

## DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

**[0017]** In the following detailed description of the illustrative, non-limiting embodiments, reference is made to the accompanying drawings that form a part hereof. Other embodiments may be utilized, and logical, structural, mechanical, electrical, and chemical changes may be made without departing from the scope of this specification. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the detailed description may omit certain information known to those skilled in the art. The following detailed description is provided without limitation, and with the scope of the illustrative embodiments being defined by the appended claims.

**[0018]** Referring generally to the drawings, this specification provides a reduced-pressure treatment system 100 utilizing a sealing drape 101 for treating a tissue site 102. The reduced-pressure treatment system 100 is presented in the context of a tissue site 102 that may include, without limitation, a wound 104 extending through the epidermis 106, the dermis 108, and reaching into a hypodermis, or subcutaneous tissue 110. The reduced-pressure treatment system 100 may include a reduced-pressure dressing 112, a reduced-pressure source 114, and a reduced-pressure delivery conduit 116. The reduced-pressure delivery conduit 116 may provide reduced pressure from the reduced-pressure source 114 to the reduced-pressure dressing 112. As will be described below, the sealing drape 101 may be a component of the reduced-pressure dressing 112 that will provide a fluid seal with the tissue site 102 while preventing the surface of the tissue site 102 from becoming saturated with moisture.

**[0019]** The term “tissue site” in this context, for example, may refer to a wound or defect located on or within any tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. A wound may include, without limitation, any irregularity with a tissue, such as an open wound, surgical incision, or diseased tissue. For example, the wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts. The term “tissue site” may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it is desired to add or promote the growth of additional tissue. For example, reduced pressure may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another location.

**[0020]** In general, components of the reduced-pressure treatment system 100 may be coupled directly or indirectly. For example, the reduced-pressure source 114 may be directly coupled to the reduced-pressure dressing 112 or indirectly coupled to the reduced-pressure dressing 112 through the reduced-pressure delivery conduit 116. Components may be fluidly coupled to each other to provide a path for transferring fluids, such as liquid or gas, between the components. In some embodiments, components may be fluidly coupled with a tube. A “tube,” as used herein, may refer to any tube, pipe, hose, conduit, or other structure with one or more lumina adapted to convey fluids between two ends. In some embodiments, components may be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Coupling may also include mechanical, thermal, electrical, or chemical coupling, such as a chemical bond.

**[0021]** “Reduced pressure” may refer to a pressure less than the ambient pressure at a tissue site being subjected to treatment. The reduced pressure may be less than the atmospheric pressure. The reduced pressure may also be less than a hydrostatic pressure at a tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Consistent with the use herein, an increase in reduced pressure or vacuum pressure may refer to a relative reduction in absolute pressure.

**[0022]** The reduced-pressure source 114 may provide reduced pressure as a part of the reduced-pressure treatment system 100. The reduced-pressure source 114 may be any device for supplying a reduced pressure, such as a vacuum pump, wall suction, micro-pump, or other source. While the amount and nature of reduced pressure applied to a tissue site may vary according to the treatment application, the reduced pressure may be between about -5 mm Hg (-667 Pa) to about -500 mm Hg (-66.7 kPa). In some embodiments, the reduced pressure may be between about -75 mm Hg (-9.9 kPa) to about -300 mm Hg (-39.9 kPa).

**[0023]** As shown in FIGURE 1, in some embodiments, the reduced-pressure dressing 112 may include a manifold 118, the sealing drape 101, and a reduced-pressure interface 122. The manifold 118 may have a first side 119 and a second side 121. The first side 119 of the manifold 118 may be placed within, over, proximate, adjacent, or in direct contact with the tissue site 102.

**[0024]** The manifold 118 maybe a substance or structure capable of applying reduced pressure to, delivering fluids to, or removing fluids from the tissue site 102. The manifold 118 may be positioned between the sealing drape 101 and the tissue site 102. The manifold 118 may be partially or fully in contact with the tissue site 102. The manifold 118 may

partially or completely fill the tissue site 102, or the manifold 118 may be placed over the tissue site 102. The manifold 118 may take many forms, and may be any size, shape, or thickness depending on a variety of factors, such as the type of treatment being implemented or the nature and size of a particular tissue site. For example, the size and shape of the manifold 118 may be adapted to the contours of deep and irregular shaped tissue sites.

**[0025]** The manifold 118 may include a plurality of flow channels or pathways configured to distribute fluids to and remove fluids from the tissue site 102. In some embodiments, the flow channels or pathways may be interconnected to improve distribution of fluids provided to or removed from the tissue site 102. The manifold 118 may be a biocompatible material that is capable of being placed in contact with the tissue site 102 and distributing reduced pressure to the tissue site 102. For example, the manifold 118 may include, without limitation, devices that have structural elements arranged to form flow channels, such as cellular foam, open-cell foam, porous tissue collections, liquids, gels, and foams that include, or cure to include, flow channels. Additionally, the manifold 118 may be a gauze, felted mat, or any other material suited to a particular biological application.

**[0026]** In some embodiments, the manifold 118 may be a porous foam having interconnected cells or pores that act as flow channels. The porous foam may be, for example, a hydrophobic material, such as a polyurethane, open-cell reticulated foam manufactured under the trade name GranuFoam® by Kinetic Concepts, Inc. of San Antonio, Texas. In some embodiments, the manifold 118 may also be used to distribute fluids such as medications, antibacterials, growth factors, and various solutions to the tissue site 102. Other layers may be included in or on the manifold 118, such as absorptive materials, wicking materials, hydrophobic materials, and hydrophilic materials.

**[0027]** In some embodiments, the manifold 118 may be made from a hydrophilic material capable of wicking fluid away from the tissue site 102 while continuing to distribute reduced pressure to the tissue site 102. The wicking properties of the manifold 118 may draw fluid away from the tissue site 102 by capillary flow or other wicking mechanisms. An example of a hydrophilic foam may be a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Texas. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics may include hydrophobic foams that have been treated or coated to provide hydrophilicity.

**[0028]** The manifold 118 may promote granulation at a tissue site when reduced-pressure is present within the reduced-pressure dressing 112. For example, any or all of the surfaces of the manifold 118 may have an uneven, coarse, or jagged profile that induce microstrains and stresses at the tissue site 102 when reduced pressure is applied through the manifold 118.

**[0029]** In some embodiments, the manifold 118 may be constructed from a bioresorbable material that may remain in a patient's body following use of the reduced-pressure dressing 112. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include, without limitation, polycarbonates, polyfumarates, and capralactones. The manifold 118 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the manifold 118 to promote cell-growth. A scaffold may be a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials may include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.

**[0030]** The sealing drape 101 may be adapted to cover the second side 121 of the manifold 118 and to seal to a peripheral surface 128 proximate the tissue site 102. Thus, the sealing drape 101 may provide a fluid seal between the reduced-pressure dressing 112 and the tissue site 102. "Fluid seal," or "seal," may refer to a seal adequate to maintain reduced pressure at a desired tissue site given the particular reduced-pressure source involved.

**[0031]** The peripheral surface 128 may be undamaged epidermis 106 peripheral to the tissue site 102. Thus, the sealing drape 101 may provide a sealed space 123 proximate to the tissue site 102 that is substantially isolated from the external environment, and capable of maintaining a reduced pressure provided by the reduced-pressure source 114. Reduced pressure applied through the manifold 118 in the sealed space 123 can promote healing by inducing macrostrain and microstrain in the tissue site 102, as well as by removing exudates and other fluids from the tissue site 102. Fluids from the tissue site 102 may be collected for disposal by a fluid canister (not shown) associated with the reduced-pressure source 114.

**[0032]** The sealing drape 101 may comprise an elastomeric material. "Elastomeric" may refer to the properties of an elastomer, such as a polymeric material that has rubber-like properties. More specifically, some elastomers have elongation rates greater than 100% and

a significant amount of resilience. The resilience of a material may refer to the ability of the material to recover from an elastic deformation.

**[0033]** In some embodiments, the reduced-pressure dressing 112 may also include additional layers (not shown) positioned between the tissue site 102 and the sealing drape 101. For example, the reduced-pressure dressing 112 may further include an absorption layer, tissue-interface layer, or additional manifold layers. The reduced-pressure dressing 112 may also include an attachment device (not shown) capable of adhering or otherwise sealing the sealing drape 101 to the peripheral surface 128. Materials suitable for use as attachment devices for adhering the sealing drape 101 about a tissue site, may include, for example, silicones and hot-melt adhesives. Other attachment devices may include, for example, hydrogels and hydrocolloids.

**[0034]** Reduced pressure may be applied to the reduced-pressure dressing 112 through the reduced-pressure interface 122. The reduced-pressure interface 122 may be fluidly coupled to the sealing drape 101 through an aperture 124 in the sealing drape 101. In the illustrative example of FIGURE 1, the aperture 124 is shown centrally located on the sealing drape 101. However, the aperture 124 may be located anywhere on the sealing drape 101, including without limitation, a peripheral portion of the sealing drape 101 that may be adjacent to an edge of the sealing drape 101. Although the aperture 124 is shown to be circular, the aperture 124 may have any shape. The shape of the aperture 124 may also be adapted to contour or substantially coordinate with the shape of the reduced-pressure delivery conduit 116. The reduced-pressure interface 122 may provide fluid communication between the sealed space 123 and the reduced-pressure delivery conduit 116 through the aperture 124.

**[0035]** The reduced pressure provided by the reduced-pressure source 114 may be delivered through the reduced-pressure delivery conduit 116 to the reduced-pressure interface 122. Thus, the reduced-pressure source 114 may be fluidly coupled to the reduced-pressure interface 122 by the reduced-pressure delivery conduit 116. In some embodiments, the reduced-pressure interface 122 may be a T.R.A.C.® Pad or Sensa T.R.A.C.® Pad available from Kinetic Concepts, Inc. of San Antonio, Texas. The reduced-pressure interface 122 may allow the reduced pressure to be delivered to the sealing drape 101 and realized within the sealed space 123 formed between the sealing drape 101 and the tissue site 102. In some embodiments, the reduced-pressure interface 122 may extend through the sealing drape 101 to the manifold 118, but numerous arrangements are possible. The reduced-pressure interface

122 may deliver the reduced pressure through the aperture 124 of the sealing drape 101 to the manifold 118 and the tissue site 102.

**[0036]** Upon application of the reduced pressure to the reduced-pressure dressing 112, fluids such as exudates from the tissue site 102 may be drawn into the manifold 118. Some amount of fluid as a consequence may also be brought into contact with the sealing drape 101, including portions of the sealing drape 101 that may be adjacent the peripheral surface 128 surrounding the tissue site 102. Moisture at the interface between the peripheral surface 128 and the sealing drape 101 may adversely affect the seal between the sealing drape 101 and the peripheral surface 128, and may increase the risk of maceration. “Maceration” or “macerating” may refer to the softening or breaking down of tissue as a result of prolonged exposure to moisture.

**[0037]** The sealing drape 101 of the reduced-pressure treatment system 100 can overcome these shortcomings and others by maintaining a fluid seal with the tissue site 102, while also preventing the peripheral surface 128 from becoming saturated with moisture. The sealing drape 101 may adhere to the tissue site 102 when wet or dry, may transmit and manage low levels of skin moisture to avoid maceration, and may be left in place for extended time periods.

**[0038]** Continuing with the embodiment of FIGURE 1, the sealing drape 101 may have an external surface 130 and an interior surface 132. The interior surface 132 may be adapted to face the tissue site 102. As previously described, the sealing drape 101 may be adapted to sealingly engage the peripheral surface 128 to provide a sealed space 123 with the tissue site 102. The interior surface 132 of the sealing drape 101 may contact the peripheral surface 128 surrounding the tissue site 102 to provide the sealed space 123. The sealing drape 101 may also be stretchable or elastic in nature. The stretchable properties of the sealing drape 101 may facilitate placement of the sealing drape 101 proximate to tissue sites having a variety of shapes, topologies, or flexibility requirements. The sealing drape 101 may be sized to extend beyond the tissue site 102 to overlap the peripheral surface 128 surrounding the tissue site 102.

**[0039]** The sealing drape 101 may include a sealing material 134 and an absorbent material 136. The sealing material 134 may be fluid permeable, may provide a substantially sheet-like structure for the sealing drape 101, and may form a part of the interior surface 132 of the sealing drape 101. The absorbent material 136 may, for example, be contained within the sealing material 134, dispersed throughout the sealing material 134, or embedded as a

sheet-like layer within the sealing material 134. The absorbent material 136 may be adapted to absorb moisture, such as exudate, from the tissue site 102 by drawing or wicking the fluid from the peripheral surface 128 of the tissue site 102.

**[0040]** The sealing material 134 may be comprised of any substantially pure hydrophobic material, and may have a variety of structures, including materials and structures that allow fluid, such as liquid or gas, to pass through the sealing material 134 without being absorbed by the sealing material 134. Herein, a substantially pure hydrophobic material may be substantially free of hydrophilic components due to the tendency for hydrophilic materials to retain fluid. For example, the substantially pure hydrophobic material of the sealing material 134 may not be a copolymer incorporating a hydrophilic component, such as a hydrophilic monomer. The sealing material 134, for example, may comprise a hydrophobic elastomer, such as a hydrophobic silicone elastomer. The hydrophobic characteristics of the sealing material 134 may prevent the sealing material 134 from directly absorbing fluid, such as exudate, from the tissue site 102, but may allow the fluid to pass through. Thus, the sealing material 134 may permit the passage of fluid away from the peripheral surface 128 and the tissue site 102 to substantially preclude any adverse affect on the seal being maintained with the tissue site 102. In this manner, the sealing material 134 may enhance the management of fluid in the reduced-pressure dressing 112 to allow for a continued fluid seal with the tissue site 102, while also protecting the tissue site 102 and surrounding areas from maceration.

**[0041]** The absorbent material 136 may be a hydrophilic material capable of absorbing fluid. The absorbent material 136 may be a separate and distinct component coupled with the sealing material 134 as described herein to provide the sealing drape 101. In some embodiments, the absorbent material 136 may comprise a super-absorbent material. For example, the absorbent material 136 may comprise one or more super-absorbent materials, such as, for example, carboxymethyl cellulose (CMC) or a carboxymethylcellulose salt, a cross-linked hydrophilic acrylic or a cross-linked hydrophilic acrylic salt, or an acrylamide.

**[0042]** When coupled with the sealing material 134, the absorbent material 136 may provide an absorption gradient to draw or otherwise wick fluid away from the tissue site 102. Fluid from the tissue site 102 may be drawn by the absorption gradient through the sealing material 134 and then be absorbed by the absorbent material 136. The absorbent material 136 may retain or bond to the fluid in conjunction with a physical or chemical change to the

absorbent material 136. The absorbent material 136 may, for example, gel, increase in viscosity, or otherwise thicken upon contact with fluid from the tissue site 102, thereby trapping the fluid. The wicking properties of the absorbent material 136 may quickly draw fluid away from the tissue site 102, and thus, may prevent the accumulation of fluid at or near the tissue site 102. In a similar manner, the sealing material 134 may facilitate the evaporation of fluid absorbed by the absorbent material 136 or otherwise transferred through the sealing material 134 towards the external surface 130 of the sealing drape 101. Since fluid from the tissue site 102 may pass through the sealing material 134 to reach the absorbent material 136 as described above, the sealing material 134 may provide a separation between the tissue site 102 and the absorbent material 136. Thus, the sealing material 134 may be positioned between the interior surface 132 of the sealing drape 101 and the absorbent material 136. Further, the sealing material 134 may substantially preclude fluid that has been absorbed by the absorbent material 136 from contacting the tissue site 102 and the peripheral surface 128.

**[0043]** The sealing material 134 may have any size, shape, or thickness depending on a variety of factors, such as the type of treatment being implemented, the nature of the tissue site 102, or the peripheral surface 128. The thickness of the sealing material 134 may be increased or decreased to optimize the effectiveness of the sealing material 134 as a separator between the tissue site 102 and the absorbent material 136. For example, in applications in which the tissue site 102 is expected to release a large amount of fluid, a thicker sealing material 134 may be desirable to restrain or prevent the fluid from contacting the tissue site 102 or the peripheral surface 128. Conversely, a thinner sealing material 134 may be desirable in applications in which a lower amount of fluid is present. For example, the sealing material 134 may be between about 100 micrometers to about 200 micrometers in thickness. The thickness of the sealing material 134 may also be adjusted according to a desired ratio of the sealing material 134 to the absorbent material 136 comprising the sealing drape 101 depending on the application. In some embodiments, the overall thickness of the sealing drape 101 including the sealing material 134 and the absorbent material 136 may be about 250 micrometers.

**[0044]** The absorbent material 136 may be dispersed throughout and/or embedded as a sheet-like layer within the sealing material 134. FIGURE 2 illustrates an embodiment of a sealing drape 201 that may include the sealing material 134 having absorbent particles 236 dispersed throughout the sealing drape 201. The absorbent particles 236 may provide the

previously described absorbent material 136. The absorbent particles 236 may have any size or shape, depending on a variety of factors, such as the nature of the tissue site 102 or the amount of fluid anticipated to be released by the tissue site 102. In applications in which the tissue site 102 releases a large amount of fluid, larger absorbent particles 236 may be desirable to provide adequate absorptive capacity for the fluid.

**[0045]** FIGURE 3 illustrates another embodiment of a sealing drape 301 in which absorbent fibers 336, such as elongate tubes, are dispersed throughout the sealing material 134. The absorbent fibers 336 may provide the previously described absorbent material 136. The absorbent fibers 336 may have any size or shape, depending on a variety of factors including the amount of fluid anticipated to be released by the tissue site 102. This specification contemplates embodiments including a mixture of absorbent particles 236 and absorbent fibers 336 dispersed within the sealing material 134 as described herein.

**[0046]** FIGURE 4 illustrates another embodiment of a sealing drape 401 in which the absorbent material 136 comprises an absorbent layer 436 positioned within the sealing material 134. The sealing drape 401 may include a first layer 134a of the sealing material 134 and a second layer 134b of the sealing material 134. The absorbent layer 436 may be positioned between the first layer 134a and the second layer 134b. The first layer 134a, the second layer 134b, and the absorbent layer 436 may each have the same or a different thickness. Thus, the absorbent layer 436 may be disposed at varying distances from the external surface 130 of the sealing drape 401 and the interior surface 132 of the sealing drape 401 depending on the thickness of each of the first and the second layer 134a, 134b.

**[0047]** The absorbent layer 436 may be provided as a nonwoven or a woven structure. For example, the absorbent layer 436 may comprise a nonwoven or a woven sheet of CMC fibers. Spaces or voids in the absorbent layer 436 may allow a reduced pressure that is applied to the reduced-pressure dressing 112 to be transferred within and through the absorbent layer 436.

**[0048]** Further, the absorbent layer 436 may have any size, shape, or thickness, depending on a variety of factors, such as the type of treatment being implemented or the nature of the tissue site 102. The size and shape of the absorbent layer 436 may be customized by a user to extend through a particular portion of the sealing drape 401. Thus, the absorbent layer 436 may be designed to cover a particular portion of the tissue site 102 or nearby tissue. For example, the width or thickness of the absorbent layer 436 may be

increased to cause a corresponding increase in fluid storage capacity of the absorbent layer 436.

**[0049]** Referring to FIGURES 2-3, in some embodiments, the absorbent particles 236 and/or the absorbent fibers 336 may be dispersed or otherwise disposed throughout the sealing material 134 in a substantially uniform manner. A substantially uniform dispersion of the absorbent particles 236 and/or the absorbent fibers 336 may reduce the distance fluid must travel from the interior surface 132 before being absorbed. As described below, in some embodiments, utilizing a configuration for the sealing drape 101 that employs the absorbent particles 236 and/or the absorbent fibers 336 and/or the absorbent layer 436 may allow a user to customize the absorption gradient through the cross section of the sealing drape 101 for a desired application. Further, in some embodiments, the absorbent particles 236 and/or the absorbent fibers 336 may be dispersed or otherwise disposed within the sealing material 134 at a desired concentration and location within the sealing drape 101 to suit a particular application.

**[0050]** FIGURE 5 illustrates another embodiment of a sealing drape 501 that may have a plurality of the previously described absorbent materials 236, 336, 436 configured as described above with the sealing material 134. The absorbent materials 236, 336, 436 may be configured with the sealing member 134 as described, and positioned in layers relative to one another within the sealing drape 501. Further, the absorbent materials 236, 336, 436 may have the same or different dimensions and include the same or different absorbent properties. In some embodiments, the plurality of absorbent materials 236, 336, 436 may increase in concentration with increasing distance from the interior surface 132 of the sealing drape 501 through the cross section of the sealing drape 501, such as, for example, from the interior surface 132 toward the external surface 130. Similarly, the sealing drape 501 may have a higher ratio of the absorbent material 236, 336, 436 to the sealing material 134 with increasing distance from the interior surface 132. In some embodiments, the absorbent materials 236, 336, 436 may exhibit increasing hydrophilicity or absorbency with increasing distance from the interior surface 132. Further, in some embodiments, the plurality of absorbent materials 236, 336, 436 may be disposed within the sealing drape 501 such that the absorbent materials 236, 336, 436 positioned farthest from the interior surface 132 absorb more fluid than those closer to the interior surface 132. For example, the absorbent layer 436 positioned furthest away from the interior surface 132, as shown in FIGURE 5, may have a higher fluid storage capacity than the absorbent materials 336, 236 positioned successively

closer to the interior surface 132. In this manner, the plurality of absorbent materials 236, 336, 436 may provide a 3-dimensional network of absorbent material to enhance the transfer of moisture away from the tissue site 102 and to retain the moisture at a maximum distance away from the tissue site 102. This configuration may be customized as described to provide a desired absorptive gradient, Moisture Vapor Transmission Rate (MVTR), and fluid storage capacity to suit a particular application.

**[0051]** FIGURE 6 illustrates another embodiment of a sealing drape 601 that may include the absorbent material 136 carried by a carrier 635. The carrier 635 including the absorbent material 136 may be positioned within the sealing material 134. For example, similar to the sealing drape 401, the sealing drape 601 may include the first layer 134a and the second layer 134b of the sealing material 134. The carrier 635 may be positioned as a layer between the first layer 134a and the second layer 134b. Thus, the carrier 635 may provide a support structure that carries the absorbent material 136. The carrier 635 may comprise any of a variety of shapes and sizes, and may comprise any suitable nonwoven or woven material. In some embodiments, the carrier 635 may comprise a nonwoven hydrophobic polypropylene material that is formed into a sheet-like structure. The carrier 635 may provide support and strength for the absorbent material 136. In some embodiments, the absorbent material 136 may be dispersed within the carrier 635 as absorbent particles 236 and/or absorbent fibers 336.

**[0052]** The sealing drape 101, 201, 301, 401, 501, and 601 may be self-sealing to the tissue site 102, or may require an additional sealing device. As discussed above, in one embodiment, the sealing material 134 of the sealing drape 101, 201, 301, 401, 501, and 601 may comprise a hydrophobic silicone elastomer, which may function as a silicone adhesive and form a direct bond with the peripheral surface 128 of the tissue site 102, the epidermis 106, or the manifold 118.

**[0053]** In some embodiments, the reduced-pressure dressing 112 may include an additional attachment device (not shown) to fluidly seal the sealing drape 101, 201, 301, 401, 501, and 601 around the tissue site 102. The attachment device may be affixed to the interior surface 132 of the sealing drape 101, 201, 301, 401, 501, and 601 and may fluidly seal the sealing drape 101, 201, 301, 401, 501, and 601 to the epidermis 106 to provide the sealed space 123 surrounding the tissue site 102. The attachment device may cover at least a portion of the interior surface 132 of the sealing drape 101, 201, 301, 401, 501, and 601. Attachment devices may include, without limitation, a medically acceptable, pressure-sensitive adhesive

that extends about a periphery, a portion of, or the entire sealing drape 101, 201, 301, 401, 501, and 601, a double-sided drape tape, paste, hydrocolloid, hydrogel, or similar sealing device. In this manner, the sealing drape 101, 201, 301, 401, 501, and 601 may be adapted to adhere to the peripheral surface 128 to secure the reduced-pressure dressing 112 to the tissue site 102.

**[0054]** In an illustrative embodiment of operation, the reduced-pressure treatment system 100 may be applied to a patient in the operating room after a surgical procedure or elsewhere. For example, the manifold 118 may be placed proximate to, within, overlying, or in contact with the tissue site 102. The sealing drape 101, 201, 301, 401, 501, and 601 may be placed over or otherwise covering the manifold 118 such that a portion of the sealing drape 101, 201, 301, 401, 501, and 601 overlays the peripheral surface 128 around the tissue site 102. The sealing drape 101, 201, 301, 401, 501, and 601 may be secured to the peripheral surface 128 in order to form a fluid seal between the tissue site 102 and the sealing drape 101, 201, 301, 401, 501, and 601. The fluid seal need only be adequate to allow the reduced-pressure treatment system 100 to maintain a reduced pressure on the tissue site 102 for a desired treatment time. The individual components of the reduced-pressure dressing 112 may be sized according to the particular application or the procedure being performed by a healthcare provider. For example, the components of the reduced-pressure dressing 112 may be sized, shaped, and configured to work in different anatomical applications such as the abdomen, chest, thighs, hip, and other locations.

**[0055]** The reduced-pressure interface 122 may be fluidly coupled to the sealing drape 101, 201, 301, 401, 501, and 601 before or after the installation of the sealing drape 101, 201, 301, 401, 501, and 601. The reduced-pressure conduit 116 may be fluidly coupled to the reduced-pressure interface 122. The reduced-pressure interface 122 may also be omitted and the reduced-pressure conduit 116 may be directly inserted into the sealing drape 101, 201, 301, 401, 501, and 601 in fluid communication with the sealed space 123. The reduced-pressure conduit 116 may be fluidly coupled to the reduced-pressure source 114. The reduced-pressure source 114 may be activated to deliver reduced pressure to the sealed space 123 provided by the sealing drape 101, 201, 301, 401, 501, and 601 surrounding the tissue site 102. In some embodiments, the reduced-pressure source 114 may be a micro-pump in or on the reduced-pressure dressing 112.

**[0056]** Upon application of the reduced pressure to the reduced-pressure dressing 112, exudates or other fluids from the tissue site 102 may be drawn into the manifold 118, the

sealing drape 101, 201, 301, 401, 501, and 601, and through the reduced-pressure interface 122. As fluids are drawn from the tissue site 102, the peripheral surface 128 as well the components of the reduced-pressure dressing 112 may become moist, including the interior surface 132 of the sealing drape 101, 201, 301, 401, 501, and 601 where the sealing drape 101, 201, 301, 401, 501, and 601 contacts the peripheral surface 128 around the tissue site 102. Because of the ability of the sealing drape 101, 201, 301, 401, 501, and 601 to transfer moisture away from the peripheral surface 128 of the tissue site 102, the sealing drape 101, 201, 301, 401, 501, and 601 may maintain a fluid seal with the tissue site 102. The sealing drape 101, 201, 301, 401, 501, and 601 may allow fluid to pass through the interior surface 132 of the sealing drape 101, 201, 301, 401, 501, and 601 to reach the absorbent material 136 contained within the sealing material 134 of the sealing drape 101, 201, 301, 401, 501, and 601, thus helping to prevent saturation of the tissue site 102 and possible maceration.

**[0057]** This specification also provides methods of manufacturing the sealing drape 101, 201, 301, 401, 501, and 601 for use with the reduced-pressure treatment system 100. In some embodiments, the method may include the steps of providing the sealing material 134, and disposing the absorbent material 136 within the sealing material 134. The absorbent material 136 may be the previously described absorbent particles 236, the absorbent fibers 336, the absorbent layer 436, or any combination thereof.

**[0058]** In embodiments utilizing the absorbent particles 236 and the absorbent fibers 336, such as the sealing drape 201, 301, the method may include the step of mixing the absorbent particles 236 and/or the absorbent fibers 336 within the sealing material 134 prior to curing or otherwise solidifying the sealing material 134. The method may further include the steps of forming the mixture of the absorbent particles 236 and/or the absorbent fibers 336 into a desired shape, such as a sheet, and curing or otherwise solidifying the mixture. In some embodiments, the absorbent particles 236 and/or the absorbent fibers 336 may be mixed within the sealing material 134 to provide a substantially uniform dispersion of the absorbent particles 236 and/or the absorbent fibers 336 within the sealing material 134. In some embodiments, the absorbent particles 236 and/or the absorbent fibers 336 may be mixed within the sealing material 134 to provide a desired concentration of the absorbent particles 236 and/or the absorbent fibers 336 within the sealing material 134 at desired location therein.

**[0059]** In embodiments utilizing the absorbent layer 436, such as the sealing drape 401, the method may include the steps of providing the first layer 134a of the sealing material

134 and providing the second layer 134b of the sealing material 134. The method may additionally include the steps of providing the absorbent layer 436, positioning the absorbent layer 436 between the first and the second layer 134a, 134b, and enclosing the first and the second layer 134a, 134b about the absorbent layer 436. In other embodiments, multiple layers of the sealing material 134 and the absorbent layers 436 may be utilized to suit a particular application.

**[0060]** In embodiments utilizing the carrier 635, such as the sealing drape 601, the method may include the step of carrying the absorbent material 136, such as the absorbent particles 236 and/or the absorbent fibers 336, with the carrier 635. For example, the absorbent particles 236 and/or the absorbent fibers 336 may be applied to the carrier 635 for support and retention by the previously described non-woven or woven structure of the carrier 635. The method may additionally include the steps of providing the first layer 134a of the sealing material 134, and providing the second layer 134b of the sealing material 134. Further, the method may include the steps of positioning the carrier 635, including the absorbent material 136, between the first and the second layer 134a, 134b, and enclosing the first and the second layer 134a, 134b about the carrier 635. In some embodiments, multiple layers of the sealing material 134 and the carrier 635, including the absorbent material 136, may be utilized to suit a particular application.

**[0061]** Although the treatment system 100 has been disclosed in the context of certain illustrative, non-limiting embodiments, various changes, substitutions, permutations, and alterations can be made without departing from the scope of this specification as defined by the appended claims. Any feature described in connection to any one embodiment may also be applicable to any other embodiment.

We claim:

1. A reduced-pressure system for treating a tissue site, the system comprising:
  - a manifold adapted to be positioned adjacent the tissue site and to distribute reduced pressure to the tissue site;
  - a sealing drape having an interior surface and an external surface, the interior surface adapted to cover the manifold and the tissue site to provide a sealed space between the interior surface of the sealing drape and the tissue site, the sealing drape further comprising:
    - a sealing material, the sealing material being hydrophobic and substantially free of hydrophilic components; and
    - an absorbent material associated with the sealing material, the sealing material being positioned between the interior surface of the sealing drape and the absorbent material; and
  - a reduced-pressure interface adapted to deliver reduced-pressure, the reduced-pressure interface in fluid communication with the sealed space and the manifold.
2. The system of claim 1, the manifold having a first side and a second side, the first side adapted to be positioned adjacent the tissue site and the second side adapted to be positioned adjacent the interior surface of the sealing drape.
3. The system of claim 1, further comprising a reduced-pressure source in fluid communication with the reduced-pressure interface.
4. The system of claim 1, wherein the sealing drape is adapted to extend beyond the tissue site and to overlap a peripheral surface surrounding the tissue site, and wherein the interior surface of the sealing drape is adapted to be positioned adjacent the peripheral surface.
5. The system of claim 1, the absorbent material disposed in the sealing material.
6. The system of claim 1, the absorbent material disposed substantially uniformly within the sealing material.

7. The system of claim 5, the absorbent material comprising a plurality of absorbent particles.
8. The system of claim 5, the absorbent material comprising a plurality of absorbent fibers.
9. The system of claim 1, the absorbent material comprising a sheet-like absorbent layer disposed between a first layer and a second layer of the sealing material.
10. The system of claim 1, the absorbent material configured to provide an absorptive gradient through the sealing drape.
11. The system of claim 1, further comprising a carrier that carries the absorbent material, the carrier and the absorbent material being disposed between a first layer and a second layer of the sealing material.
12. The system of claim 11, the carrier comprising a hydrophobic polypropylene sheet.
13. The system of claim 1, further comprising a plurality of absorbent materials associated with the sealing material of the sealing drape, the plurality of absorbent materials having an absorptive capacity that increases with increasing distance through a cross section of the sealing drape from the interior surface of the sealing drape.
14. The system of claim 1, wherein the absorbent material comprises a three-dimensional structure of interconnected absorbent fibers, absorbent particles, and sheet-like absorbent layers.
15. The system of claim 1, wherein the sealing material is fluid permeable.
16. The system of claim 1, wherein the sealing material comprises an elastomeric material.
17. The system of claim 1, wherein the sealing material comprises a hydrophobic silicone elastomer.
18. The system of claim 1, wherein the sealing material of the sealing drape is adapted to provide evaporation of fluid retained in the absorbent material through the external surface of the sealing drape.

19. A sealing drape for treating a tissue site, the sealing drape comprising:
  - an interior surface and an external surface, the interior surface adapted to be positioned adjacent a peripheral surface surrounding the tissue site and to overlap the peripheral surface to provide a sealed space between the sealing drape and the tissue site;
  - a sealing material, the sealing material comprising a fluid permeable hydrophobic material substantially free of hydrophilic components; and
  - an absorbent material disposed in the sealing material, the sealing material being positioned between the interior surface of the sealing drape and the absorbent material, the absorbent material adapted to absorb fluid communicated through the sealing material.
20. The sealing drape of claim 19, the absorbent material disposed substantially uniformly within the sealing material.
21. The sealing drape of claim 19, the absorbent material comprising a plurality of absorbent particles.
22. The sealing drape of claim 19, the absorbent material comprising a plurality of absorbent fibers.
23. The sealing drape of claim 19, the absorbent material comprising a sheet-like absorbent layer disposed between a first layer and a second layer of the sealing material.
24. The sealing drape of claim 19, the absorbent material configured to provide an absorptive gradient through the sealing drape.
25. The sealing drape of claim 19, further comprising a carrier that carries the absorbent material, the carrier and the absorbent material being disposed between a first layer and a second layer of the sealing material.
26. The sealing drape of claim 25, the carrier comprising a hydrophobic polypropylene sheet.
27. The sealing drape of claim 19, further comprising a plurality of absorbent materials disposed in the sealing material of the sealing drape, the absorbent materials having an absorptive capacity that increases with increasing distance through a cross section of the

sealing drape from the interior surface of the sealing drape.

28. The sealing drape of claim 19, wherein the absorbent material comprises a three-dimensional structure of interconnected absorbent fibers, absorbent particles, and sheet-like absorbent layers.
29. The sealing drape of claim 19, wherein the sealing material comprises an elastomeric material.
30. The sealing drape of claim 19, wherein the sealing material comprises a hydrophobic silicone elastomer.
31. The sealing drape of claim 19, wherein the sealing material of the sealing drape is adapted to provide evaporation of fluid retained in the absorbent material through the external surface of the sealing drape.

32. A method of manufacturing a sealing drape for treating a tissue site, the method comprising:
  - providing a sealing material being hydrophobic and substantially free of hydrophilic components;
  - providing an absorbent material; and
  - disposing the absorbent material in the sealing material.
33. The method of claim 32, the step of disposing the absorbent material in the sealing material comprising:
  - mixing the absorbent material and the sealing material together to provide a substantially uniform dispersion of absorbent material within the sealing material; and
  - curing the mixture.
34. The method of claim 33, further comprising the step of forming a sheet-like layer from the mixture.
35. The method of claim 33, the absorbent material comprising a plurality of absorbent fibers.
36. The method of claim 33, the absorbent material comprising a plurality of absorbent particles.
37. The method of claim 32, further comprising providing a first layer of the sealing material and providing a second layer of the sealing material, wherein the step of disposing the absorbent material in the sealing material comprises positioning the absorbent material between the first layer of the sealing material and the second layer of the sealing material.
38. The method of claim 37, the absorbent material comprising a sheet-like absorbent layer.
39. The method of claim 32, further comprising providing a first layer of the sealing material and providing a second layer of the sealing material, wherein the step of disposing the absorbent material within the sealing material comprises:
  - providing a carrier;
  - carrying the absorbent material with the carrier; and

positioning the carrier and the absorbent material between the first layer of the sealing material and the second layer of the sealing material.

40. The method of claim 39, wherein the carrier comprises a hydrophobic polypropylene sheet.

41. A reduced-pressure system for treating a tissue site, the system comprising:  
a manifold adapted to be positioned adjacent the tissue site and to distribute reduced pressure to the tissue site;  
a sealing drape having an interior surface and an external surface, the interior surface adapted to be positioned adjacent a peripheral surface surrounding the tissue site and to cover the manifold and the tissue site to provide a sealed space between the interior surface and the tissue site, wherein the sealing drape is adapted to extend beyond the tissue site and to overlap the peripheral surface, the sealing drape further comprising:  
a sealing material, the sealing material being hydrophobic and substantially free of hydrophilic components; and  
an absorbent material associated with the sealing material, the sealing material being positioned between the interior surface of the sealing drape and the absorbent material; and  
a reduced-pressure interface adapted to deliver reduced-pressure, the reduced-pressure interface in fluid communication with the sealed space and the manifold.

42. A method for treating a tissue site, comprising:

positioning a sealing drape adjacent a peripheral surface surrounding the tissue site, the sealing drape extending beyond the tissue site and overlapping the peripheral surface; and  
transferring moisture away from the peripheral surface through the sealing drape.






FIG. 1








FIG. 4





# INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2013/074763

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. A61F13/00 A61M1/00 A61M27/00 A61F13/02  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
A61F A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/146441 A1 (KCI LICENSING INC [US]; RANDOLPH LARRY TAB [US]; LONG JUSTIN ALEXANDER) 3 December 2009 (2009-12-03) paragraphs [0002], [0024], [0025]; figure 1 -----	1-4,16, 17,41
A	US 2011/301556 A1 (LICHTENSTEIN ISAAC [US]) 8 December 2011 (2011-12-08) figures 7A-14 paragraphs [0002], [0110] - [0117] -----	5-15, 18-40
X		1-4,41
A		5-40



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

18 February 2014

28/03/2014

Name and mailing address of the ISA/  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Gennari, Silvia

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2013/074763

### Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: **42**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy**
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/074763

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 2009146441	A1	03-12-2009	AU 2009251242 A1	03-12-2009
			AU 2009262874 A1	30-12-2009
			AU 2009262875 A1	30-12-2009
			AU 2009262876 A1	30-12-2009
			AU 2009262877 A1	30-12-2009
			AU 2009262878 A1	30-12-2009
			AU 2009262879 A1	30-12-2009
			AU 2009262880 A1	30-12-2009
			AU 2009262881 A1	30-12-2009
			AU 2009262882 A1	30-12-2009
			AU 2009262884 A1	30-12-2009
			CA 2725556 A1	30-12-2009
			CA 2725561 A1	30-12-2009
			CA 2725566 A1	30-12-2009
			CA 2725943 A1	30-12-2009
			CA 2725945 A1	30-12-2009
			CA 2726027 A1	30-12-2009
			CA 2726038 A1	30-12-2009
			CA 2726042 A1	30-12-2009
			CA 2726142 A1	30-12-2009
			CA 2726225 A1	03-12-2009
			CA 2726240 A1	30-12-2009
			CN 102026675 A	20-04-2011
			CN 102036697 A	27-04-2011
			CN 102036698 A	27-04-2011
			CN 102036699 A	27-04-2011
			CN 102036700 A	27-04-2011
			CN 102046118 A	04-05-2011
			CN 102046119 A	04-05-2011
			CN 102046216 A	04-05-2011
			CN 102046217 A	04-05-2011
			CN 102046219 A	04-05-2011
			CN 102089017 A	08-06-2011
			CN 103405813 A	27-11-2013
			CN 103417332 A	04-12-2013
			CN 103480048 A	01-01-2014
			CN 103536975 A	29-01-2014
			EP 2278948 A1	02-02-2011
			EP 2279016 A1	02-02-2011
			EP 2279017 A1	02-02-2011
			EP 2279018 A1	02-02-2011
			EP 2279019 A2	02-02-2011
			EP 2282788 A1	16-02-2011
			EP 2285323 A1	23-02-2011
			EP 2285430 A2	23-02-2011
			EP 2285431 A1	23-02-2011
			EP 2285432 A1	23-02-2011
			EP 2285433 A2	23-02-2011
			EP 2305327 A2	06-04-2011
			EP 2305328 A2	06-04-2011
			EP 2305329 A2	06-04-2011
			EP 2305330 A2	06-04-2011
			EP 2319550 A1	11-05-2011
			EP 2529767 A2	05-12-2012
			EP 2594298 A1	22-05-2013
			EP 2630979 A1	28-08-2013
			EP 2659915 A1	06-11-2013
			EP 2666488 A2	27-11-2013

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/074763

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
	JP	4981992 B2	25-07-2012
	JP	5016137 B2	05-09-2012
	JP	5199462 B2	15-05-2013
	JP	5219104 B2	26-06-2013
	JP	5219105 B2	26-06-2013
	JP	5313340 B2	09-10-2013
	JP	5378506 B2	25-12-2013
	JP	2011521736 A	28-07-2011
	JP	2011521737 A	28-07-2011
	JP	2011521738 A	28-07-2011
	JP	2011521739 A	28-07-2011
	JP	2011521740 A	28-07-2011
	JP	2011521741 A	28-07-2011
	JP	2011521742 A	28-07-2011
	JP	2011521743 A	28-07-2011
	JP	2011523574 A	18-08-2011
	JP	2011523870 A	25-08-2011
	JP	2011526798 A	20-10-2011
	JP	2013116339 A	13-06-2013
	JP	2013138873 A	18-07-2013
	JP	2013144120 A	25-07-2013
	JP	2013208461 A	10-10-2013
	JP	2013215585 A	24-10-2013
	JP	2013226421 A	07-11-2013
	JP	2013226422 A	07-11-2013
	JP	2013236946 A	28-11-2013
	JP	2014000413 A	09-01-2014
	KR	20110011684 A	08-02-2011
	KR	20110011696 A	08-02-2011
	KR	20110016963 A	18-02-2011
	KR	20110018359 A	23-02-2011
	KR	20110018392 A	23-02-2011
	KR	20110019762 A	28-02-2011
	KR	20110022642 A	07-03-2011
	KR	20110022643 A	07-03-2011
	KR	20110028468 A	18-03-2011
	KR	20110033126 A	30-03-2011
	KR	20110033129 A	30-03-2011
	RU	2010146765 A	20-07-2012
	RU	2010146770 A	10-07-2012
	RU	2010146771 A	10-07-2012
	TW	200950823 A	16-12-2009
	TW	200950829 A	16-12-2009
	TW	200950830 A	16-12-2009
	TW	200950831 A	16-12-2009
	TW	200950832 A	16-12-2009
	TW	200950833 A	16-12-2009
	TW	201002249 A	16-01-2010
	TW	201002276 A	16-01-2010
	TW	201002375 A	16-01-2010
	TW	201002376 A	16-01-2010
	TW	201002377 A	16-01-2010
	US	2009293887 A1	03-12-2009
	US	2009299249 A1	03-12-2009
	US	2009299255 A1	03-12-2009
	US	2009299256 A1	03-12-2009
	US	2009299257 A1	03-12-2009
	US	2009299307 A1	03-12-2009

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2013/074763

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
	US	2009299308 A1	03-12-2009
	US	2009299340 A1	03-12-2009
	US	2009299341 A1	03-12-2009
	US	2009299342 A1	03-12-2009
	US	2009312728 A1	17-12-2009
	US	2012029487 A1	02-02-2012
	US	2012110822 A1	10-05-2012
	US	2012130326 A1	24-05-2012
	US	2012165765 A1	28-06-2012
	US	2012191054 A1	26-07-2012
	US	2012203189 A1	09-08-2012
	US	2012220964 A1	30-08-2012
	US	2012271255 A1	25-10-2012
	US	2012277699 A1	01-11-2012
	US	2013190668 A1	25-07-2013
	US	2013197457 A1	01-08-2013
	WO	2009146441 A1	03-12-2009
	WO	2009158123 A2	30-12-2009
	WO	2009158124 A1	30-12-2009
	WO	2009158125 A1	30-12-2009
	WO	2009158126 A1	30-12-2009
	WO	2009158127 A1	30-12-2009
	WO	2009158128 A2	30-12-2009
	WO	2009158129 A1	30-12-2009
	WO	2009158130 A1	30-12-2009
	WO	2009158131 A1	30-12-2009
	WO	2009158133 A2	30-12-2009
<hr style="border: 0; border-top: 1px dashed black; margin-bottom: 5px;"/> <b>US 2011301556 A1 08-12-2011 NONE</b>			